Clinical Scorecard: Temporal and Spatial Examination of Crohn's Disease Identifies PECAM2 Signaling as a Key Factor in the Transition from Inflammation to Fibrosis
At a Glance
Category
Detail
Condition
Crohn's disease (CD), a chronic inflammatory bowel disease complicated by fibrotic strictures
Key Mechanisms
PECAM2 signaling via PECAM1–CD38 interaction drives fibrosis progression; ApoA signaling maintains epithelial and stromal homeostasis
Target Population
Patients with Crohn's disease, particularly those with stricturing complications
Care Setting
Surgical and medical management settings including research and experimental therapeutic contexts
Key Highlights
Fibrotic strictures in CD result from chronic inflammation leading to fibrosis in the mesenchymal compartment.
Spatial transcriptomics combined with single-cell RNA sequencing identified PECAM2 signaling as a key driver of inflammation-to-fibrosis transition.
Inhibition of CD38 signaling in a TNBS-induced chronic colitis mouse model reduced colitis symptoms and colon thickening.
Guideline-Based Recommendations
Diagnosis
Use spatial transcriptomics and single-cell RNA sequencing to characterize tissue inflammation and fibrosis in CD.
Histopathological examination of surgical specimens to identify regions of healthy, inflamed, and fibrotic tissue.
Management
Current treatment of strictures is primarily surgical or via balloon dilatation due to lack of effective medical therapies.
Targeting PECAM2 signaling, specifically CD38 inhibition, shows potential to reduce fibrosis and strictures.
Monitoring & Follow-up
Monitor progression of fibrosis through imaging and histological assessment of intestinal tissue.
Evaluate response to experimental therapies targeting PECAM2/CD38 signaling pathways.
Risks
Fibrotic strictures develop in over 50% of CD patients, often requiring invasive interventions.
Lack of specific medical treatments for fibrosis increases risk of surgery and complications.
Patient & Prescribing Data
Patients with Crohn's disease exhibiting stricturing complications and chronic inflammation
Experimental CD38 inhibitors may reduce fibrosis development and colitis severity, representing a novel therapeutic avenue.
Clinical Best Practices
Integrate spatial transcriptomics and single-cell RNA sequencing for comprehensive tissue analysis in CD.
Consider targeting PECAM2/CD38 signaling pathways to prevent or reduce fibrosis progression.
Use surgical specimens to study disease progression from healthy to fibrotic tissue for personalized treatment planning.
